Cancer drugs offer new hope for Crohn's disease and sarcoidosis
Sunday, December 5, 2010 - 13:30
in Health & Medicine
A new study offers insight into a new treatment avenue for Crohn's Disease and sarcoidosis. While the loss of NOD2 increases the risk of developing Crohn's disease, increased activity of this gene is also thought to exacerbate symptoms. Scientists have identified two existing FDA-approved drugs that are able to inhibit the activity of NOD2's binding partner, the kinase RIP2, and therefore, also inhibit the activity of NOD2.